A phase 1/2 first in human study of ADI-270, an armored allogeneic anti-CD70 chimeric antigen receptor (CAR)γδT cell therapy, in patients (pts) with relapsed or refractory (R/R) clear cell renal cell carcinoma (ccRCC) (trial in progress)

ADI-270 - Adicet Bio

https://www.abstractsonline.com/pp8/#!/20273/presentation/10587

Sumanta K. Pal1; Benjamin Garmezy2; Helen Budworth3; Xiaoyan Du3; Shon Green3; Kevin Nishimoto3; Jackie Kennedy-Wilde3; Blake T. Aftab3; Julia Maltzman3; Gregory S. Vosganian3; Brian Rini4

Mar 26, 2025